CPRX Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of -4506.12%. Catalyst Pharmaceuticals's return on equity of 27.81% beat BridgeBio Pharma's return on equity of --.

Catalyst Pharmaceuticals has a consensus price target of $33.33, signalling upside risk potential of 29.6%. On the other hand BridgeBio Pharma has an analysts' consensus of $54.06 which suggests that it could grow by 47.15%. Given that BridgeBio Pharma has higher upside potential than Catalyst Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.836, which suggesting that the stock is 16.449% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.858%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are larger than BridgeBio Pharma quarterly revenues of $5.9M. Catalyst Pharmaceuticals's net income of $55.9M is higher than BridgeBio Pharma's net income of -$265.1M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 19.63x while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 6.53x versus 30.81x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of 16.9%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Corcept Therapeutics's return on equity of 23.78%.

Catalyst Pharmaceuticals has a consensus price target of $33.33, signalling upside risk potential of 29.6%. On the other hand Corcept Therapeutics has an analysts' consensus of $99.75 which suggests that it could grow by 71.04%. Given that Corcept Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.836, which suggesting that the stock is 16.449% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.816%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Catalyst Pharmaceuticals's net income of $55.9M is higher than Corcept Therapeutics's net income of $30.7M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 19.63x while Corcept Therapeutics's PE ratio is 47.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 6.53x versus 9.81x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of 45.98%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Halozyme Therapeutics's return on equity of 162.37%.

Catalyst Pharmaceuticals has a consensus price target of $33.33, signalling upside risk potential of 29.6%. On the other hand Halozyme Therapeutics has an analysts' consensus of $66.11 which suggests that it could grow by 1.96%. Given that Catalyst Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Halozyme Therapeutics.

Catalyst Pharmaceuticals has a beta of 0.836, which suggesting that the stock is 16.449% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.323, suggesting its more volatile than the S&P 500 by 32.293%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Halozyme Therapeutics quarterly revenues of $298M. Catalyst Pharmaceuticals's net income of $55.9M is lower than Halozyme Therapeutics's net income of $137M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 19.63x while Halozyme Therapeutics's PE ratio is 18.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 6.53x versus 8.26x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 39.44% compared to Catalyst Pharmaceuticals's net margin of -46.06%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Catalyst Pharmaceuticals has a consensus price target of $33.33, signalling upside risk potential of 29.6%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $59.42 which suggests that it could grow by 84.13%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.836, which suggesting that the stock is 16.449% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.122%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.8M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Catalyst Pharmaceuticals's net income of $55.9M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 19.63x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 6.53x versus 6.84x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.